Pacira Pharmaceuticals Inc. Appoints Industry Expert Yvonne Greenstreet to its Board of Directors
“We are delighted to have Yvonne join as our newest board member,” said
Dr.
As senior vice president and head of medicines development at Pfizer,
Dr. Greenstreet was on the global executive team for the
Dr. Greenstreet was at GlaxoSmithKine (GSK) for 18 years, where she was
senior vice president and chief of strategy for research and
development, serving on the corporate executive investment committee.
She was responsible for enabling strategy development and execution to
achieve GSK’s goal of delivering five to seven new medicines per year
with increasing returns on investment. Previously, Dr. Greenstreet
served in various positions of increasing responsibility at GSK,
including senior vice president for medicine development, where she led
the creation of a new global unit that had responsibility for GSK’s
musculoskeletal, endocrine, gastrointestinal, ophthalmology and
urological disease areas. She spearheaded GSK’s entry into
immune-inflammation and biologics with the in-licensing of Benlysta for
patients with lupus and Arzerra for patients with chronic lymphocytic
leukemia. Prior to this role, she was chief medical officer for GSK
Dr. Greenstreet is highly regarded for her vision and ability in
identifying emerging opportunities, her expertise in drug development
and her success in building highly functioning organizations. She
trained as a physician and earned her medical degree from
About Pacira
Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about our plans and
expectations regarding EXPAREL, and other statements containing the
words “believes,” “anticipates,” “plans,” “expects,” and similar
expressions, constitute forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including risks
relating to: the success of our sales and manufacturing efforts in
support of the commercialization of EXPAREL; the rate and degree of
market acceptance of EXPAREL; the size and growth of the potential
markets for EXPAREL and our ability to serve those markets; our plans to
expand the indications of EXPAREL, including for nerve block and the
related timing and success of an sNDA; our plans to evaluate, develop
and pursue additional DepoFoam-based product candidates; clinical
studies in support of an existing or potential DepoFoam-based product;
our plans to continue to manufacture and provide support services for
our commercial partners who have licensed DepoCyt(e); our
commercialization and marketing capabilities; and other factors
discussed in the “Risk Factors” of our most recent Annual Report on Form
10-K for the fiscal year ended
Source:
Company Contact:
Pacira Pharmaceuticals, Inc.
Jessica
Cho, 973-254-3574
or
Media Contact:
Pure
Communications, Inc.
Susan Heins, 864-286-9597